Company Filing History:
Years Active: 2024-2025
Title: Catherine Margaret Mageeney: Innovator in Antibody Technology
Introduction
Catherine Margaret Mageeney is a prominent inventor based in Livermore, CA (US). She has made significant contributions to the field of antibody technology, particularly in the development of single-domain antibodies. With a total of 2 patents, her work focuses on innovative methods for targeting and purifying antibodies for therapeutic applications.
Latest Patents
Catherine's latest patents include groundbreaking advancements in lung-targeting and brain-targeting single-domain antibodies. The first patent, titled "Lung-targeting single-domain antibodies and purification methods," discloses single-domain antibodies (sdABs) designed to target human or mammalian lung tissue. This patent outlines constructs and methods for binding and transporting other sdABs or cargo with beneficial functionalities. It also describes methods for treating, diagnosing, or prophylactically addressing diseases, conditions, or malignancies, along with a purification method for in vivo treatment or testing.
The second patent, "Brain-targeting single domain antibodies and purification methods," provides sdAbs that can pass the blood-brain barrier in humans or mammals. This patent details methods for binding to brain cells and transporting biochemical or pharmaceutical species with beneficial functionalities. It also emphasizes the potential for treating, diagnosing, or prophylactically addressing diseases, malignancies, or conditions affecting the brain.
Career Highlights
Catherine is currently employed at National Technology & Engineering Solutions of Sandia, LLC, where she continues to advance her research in antibody technology. Her work has garnered attention for its potential applications in medical treatments and diagnostics.
Collaborations
Catherine collaborates with talented individuals in her field, including Brooke Nicole Harmon and Maxwell Stefan. Their combined expertise contributes to the innovative research and development of antibody technologies.
Conclusion
Catherine Margaret Mageeney is a trailblazer in the field of antibody technology, with a focus on developing targeted therapies for critical health issues. Her patents reflect her commitment to advancing medical science and improving patient outcomes.